Rapamycin inhibits release of tumor necrosis factor-α from human vascular smooth muscle cells

Jonathan R. Adkins, Manuel R Castresana, Zhongbiao Wang, Walter H. Newman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Neointimal proliferation with plaque formation is the principal cause of coronary artery disease. In the neointima, inflammatory cytokines like tumor necrosis factor-α (TNF-α) are expressed by vascular smooth muscle cells (VSMCs). These cytokines stimulate proliferation and migration of VSMCs, events that are crucial to neointima formation. Stents, liberating rapamycin, have been shown to reduce neointima formation in human coronary arteries. The purpose of this study was to determine if rapamycin could inhibit the production of TNF-α by VSMCs. With institutional review board approval, VSMCs were cultured from saphenous vein segments obtained from five patients. Cells were identified as VSMC by immunostaining for smooth muscle α-actin. Cells were exposed to bacterial lipopolysaccharide (LPS), LPS plus rapamycin, or LPS plus isoproterenol for 24 hours. Cells with no treatment served as controls. The culture medium was then removed and analyzed for TNF-α. Additionally, the effect of treatment on viability was determined by assay of mitochondrial activity. TNF-α released into the culture medium is expressed as pg TNF-α/mg cell protein. Statistical analysis was by ANOVA. In control cells, TNF-α was undetectable in the culture medium. The addition of LPS (10 μg/mL) increased TNF-α release to 4312 ± 705 pg/mg at 24 hours. The addition of 1 ng/mL rapamycin with LPS reduced TNF-α production 50 per cent (P < 0.01 vs LPS alone). A similar reduction of TNF-α release was seen with 1 μM isoproterenol. LPS, rapamycin, or isoproterenol did not affect cell viability. These data show that rapamycin effectively inhibits the release of TNF-α from VSMCs stimulated with inflammatory mediators like LPS. Rapamycin is as effective as agents that raise intracellular cyclic AMP (e.g., isoproterenol). Therefore, a potential mechanism for the effectiveness of rapamycin-releasing stents is reduction of inflammatory cytokine expression by VSMCs.

Original languageEnglish (US)
Pages (from-to)384-387
Number of pages4
JournalAmerican Surgeon
Volume70
Issue number5
StatePublished - Dec 1 2004

Fingerprint

Sirolimus
Vascular Smooth Muscle
Smooth Muscle Myocytes
Tumor Necrosis Factor-alpha
Lipopolysaccharides
Isoproterenol
Neointima
Culture Media
Cytokines
Stents
human TNF protein
Research Ethics Committees
Saphenous Vein
Cyclic AMP
Smooth Muscle
Actins
Coronary Artery Disease
Cell Survival
Coronary Vessels
Analysis of Variance

ASJC Scopus subject areas

  • Surgery

Cite this

Rapamycin inhibits release of tumor necrosis factor-α from human vascular smooth muscle cells. / Adkins, Jonathan R.; Castresana, Manuel R; Wang, Zhongbiao; Newman, Walter H.

In: American Surgeon, Vol. 70, No. 5, 01.12.2004, p. 384-387.

Research output: Contribution to journalArticle

Adkins, Jonathan R. ; Castresana, Manuel R ; Wang, Zhongbiao ; Newman, Walter H. / Rapamycin inhibits release of tumor necrosis factor-α from human vascular smooth muscle cells. In: American Surgeon. 2004 ; Vol. 70, No. 5. pp. 384-387.
@article{8236bde5a5bf4f1f9889705dadf7eab0,
title = "Rapamycin inhibits release of tumor necrosis factor-α from human vascular smooth muscle cells",
abstract = "Neointimal proliferation with plaque formation is the principal cause of coronary artery disease. In the neointima, inflammatory cytokines like tumor necrosis factor-α (TNF-α) are expressed by vascular smooth muscle cells (VSMCs). These cytokines stimulate proliferation and migration of VSMCs, events that are crucial to neointima formation. Stents, liberating rapamycin, have been shown to reduce neointima formation in human coronary arteries. The purpose of this study was to determine if rapamycin could inhibit the production of TNF-α by VSMCs. With institutional review board approval, VSMCs were cultured from saphenous vein segments obtained from five patients. Cells were identified as VSMC by immunostaining for smooth muscle α-actin. Cells were exposed to bacterial lipopolysaccharide (LPS), LPS plus rapamycin, or LPS plus isoproterenol for 24 hours. Cells with no treatment served as controls. The culture medium was then removed and analyzed for TNF-α. Additionally, the effect of treatment on viability was determined by assay of mitochondrial activity. TNF-α released into the culture medium is expressed as pg TNF-α/mg cell protein. Statistical analysis was by ANOVA. In control cells, TNF-α was undetectable in the culture medium. The addition of LPS (10 μg/mL) increased TNF-α release to 4312 ± 705 pg/mg at 24 hours. The addition of 1 ng/mL rapamycin with LPS reduced TNF-α production 50 per cent (P < 0.01 vs LPS alone). A similar reduction of TNF-α release was seen with 1 μM isoproterenol. LPS, rapamycin, or isoproterenol did not affect cell viability. These data show that rapamycin effectively inhibits the release of TNF-α from VSMCs stimulated with inflammatory mediators like LPS. Rapamycin is as effective as agents that raise intracellular cyclic AMP (e.g., isoproterenol). Therefore, a potential mechanism for the effectiveness of rapamycin-releasing stents is reduction of inflammatory cytokine expression by VSMCs.",
author = "Adkins, {Jonathan R.} and Castresana, {Manuel R} and Zhongbiao Wang and Newman, {Walter H.}",
year = "2004",
month = "12",
day = "1",
language = "English (US)",
volume = "70",
pages = "384--387",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "5",

}

TY - JOUR

T1 - Rapamycin inhibits release of tumor necrosis factor-α from human vascular smooth muscle cells

AU - Adkins, Jonathan R.

AU - Castresana, Manuel R

AU - Wang, Zhongbiao

AU - Newman, Walter H.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Neointimal proliferation with plaque formation is the principal cause of coronary artery disease. In the neointima, inflammatory cytokines like tumor necrosis factor-α (TNF-α) are expressed by vascular smooth muscle cells (VSMCs). These cytokines stimulate proliferation and migration of VSMCs, events that are crucial to neointima formation. Stents, liberating rapamycin, have been shown to reduce neointima formation in human coronary arteries. The purpose of this study was to determine if rapamycin could inhibit the production of TNF-α by VSMCs. With institutional review board approval, VSMCs were cultured from saphenous vein segments obtained from five patients. Cells were identified as VSMC by immunostaining for smooth muscle α-actin. Cells were exposed to bacterial lipopolysaccharide (LPS), LPS plus rapamycin, or LPS plus isoproterenol for 24 hours. Cells with no treatment served as controls. The culture medium was then removed and analyzed for TNF-α. Additionally, the effect of treatment on viability was determined by assay of mitochondrial activity. TNF-α released into the culture medium is expressed as pg TNF-α/mg cell protein. Statistical analysis was by ANOVA. In control cells, TNF-α was undetectable in the culture medium. The addition of LPS (10 μg/mL) increased TNF-α release to 4312 ± 705 pg/mg at 24 hours. The addition of 1 ng/mL rapamycin with LPS reduced TNF-α production 50 per cent (P < 0.01 vs LPS alone). A similar reduction of TNF-α release was seen with 1 μM isoproterenol. LPS, rapamycin, or isoproterenol did not affect cell viability. These data show that rapamycin effectively inhibits the release of TNF-α from VSMCs stimulated with inflammatory mediators like LPS. Rapamycin is as effective as agents that raise intracellular cyclic AMP (e.g., isoproterenol). Therefore, a potential mechanism for the effectiveness of rapamycin-releasing stents is reduction of inflammatory cytokine expression by VSMCs.

AB - Neointimal proliferation with plaque formation is the principal cause of coronary artery disease. In the neointima, inflammatory cytokines like tumor necrosis factor-α (TNF-α) are expressed by vascular smooth muscle cells (VSMCs). These cytokines stimulate proliferation and migration of VSMCs, events that are crucial to neointima formation. Stents, liberating rapamycin, have been shown to reduce neointima formation in human coronary arteries. The purpose of this study was to determine if rapamycin could inhibit the production of TNF-α by VSMCs. With institutional review board approval, VSMCs were cultured from saphenous vein segments obtained from five patients. Cells were identified as VSMC by immunostaining for smooth muscle α-actin. Cells were exposed to bacterial lipopolysaccharide (LPS), LPS plus rapamycin, or LPS plus isoproterenol for 24 hours. Cells with no treatment served as controls. The culture medium was then removed and analyzed for TNF-α. Additionally, the effect of treatment on viability was determined by assay of mitochondrial activity. TNF-α released into the culture medium is expressed as pg TNF-α/mg cell protein. Statistical analysis was by ANOVA. In control cells, TNF-α was undetectable in the culture medium. The addition of LPS (10 μg/mL) increased TNF-α release to 4312 ± 705 pg/mg at 24 hours. The addition of 1 ng/mL rapamycin with LPS reduced TNF-α production 50 per cent (P < 0.01 vs LPS alone). A similar reduction of TNF-α release was seen with 1 μM isoproterenol. LPS, rapamycin, or isoproterenol did not affect cell viability. These data show that rapamycin effectively inhibits the release of TNF-α from VSMCs stimulated with inflammatory mediators like LPS. Rapamycin is as effective as agents that raise intracellular cyclic AMP (e.g., isoproterenol). Therefore, a potential mechanism for the effectiveness of rapamycin-releasing stents is reduction of inflammatory cytokine expression by VSMCs.

UR - http://www.scopus.com/inward/record.url?scp=2542612167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542612167&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 384

EP - 387

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 5

ER -